
|Videos|April 5, 2016
Dr. John Mascarenhas on the COMFORT-I/II Studies for Ruxolitinib in Myelofibrosis
Author(s)John Mascarenhas, MD
The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis.
Advertisement
John Mascarenhas, MD, associate professor of medicine, Mount Sinai Hospital, discusses the COMFORT-I and COMFORT-II studies. The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis. In both studies ruxolitinib reduced splenomegaly and improving symptoms, mostly by down-modulating inflammitory cytokine signaling.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































